Cas no 1094-61-7 (β-Nicotinamide Mononucleotide)
β-Nicotinamide Mononucleotide Chemical and Physical Properties
Names and Identifiers
-
- Pyridinium,3-(aminocarbonyl)-1-(5-O-phosphono-b-D-ribofuranosyl)-, inner salt
- beta-Nicotinamide Mononucleotide
- NMN
- β-nicotinamide D-ribonucleotide
- β-Nicotinamide Monon
- β-Nicotinamide Mononucleotide
- β-NM
- β-NMN
- Nicotinamide ribotide
- 3-(Aminocarbonyl)-1-(5-O-phosphonato-beta-D-ribofuranosyl)pyridinium
- 3-carbamoyl-1-(5-O-phosphonopentofuranosyl)pyridinium
- 3-carbamoyl-1-[5-O-(hydroxyphosphinato)-beta-D-ribofuranosyl]pyridinium
- Nicotinamide mononucleotide
- Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt
- β-Nicotinamide ribose monophosphate
- Nicotinamide-1-ium-1-β-D-ribofuranoside 5′-phosphate
- Nicotinamide ribonucleoside 5'-phosphate
- Nicotinamide ribonucleotide
- beta-D-NMN
- beta-NMN
- β-D-NMN
- NMN zwitterion
- Nicotinamide nucleotide
- Nicotimide mononucleotide
- Nicotinamide mononuclotide
- 1-[5-O-(Hydroxyphosphinato)pentofuranosyl]pyridin-1-ium-3-carboximidate
- 1-[(2R,3R,4S,5R)-3,4-Dihydroxy-5-[[hydroxy(oxido)phosphoryl]oxymethyl]oxolan-2-yl]pyridin-1-ium-3-ca
- CID 138396994
- β-NicotinamideMononucleotide
- β-Nicotinamide Mononucleotide ，NMN
- beta-nicotinamide D-ribonucleotide
- nicotinamide D-ribonucleotide
- beta-Nicotinamide ribonucleotide
- 2KG6QX4W0V
- ((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-d
- β-Nicotinamide Mononucleotide(NMN)
- β-Nicotinamide Mononucleotide (NMN)
- BETA-NICOTINAMIDE RIBOSE MONOPHOSPHATE
- B-NICOTINAMIDE MONONUCLEOTIDE
- NICOTINAMIDE-1-IUM-1-BETA-D-RIBOFURANOSIDE 5'-PHOSPHATE
- 3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1λ?-pyridin-1-ylium
- Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-.beta.-D-ribofuranosyl)-, inner salt
- DTXSID50911152
- H11919
- .BETA.-NMN
- -NM;NMN
- C00455
- 1094-61-7
- AC-35057
- [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methylhydrogenphosphate
- N1123
- Q21547155
- fA-Nicotinamide Mononucleotide
- AKOS015896881
- NMN [MI]
- ((2R,3S,4R,5R)-5-(3-carbamoylpyridinium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate
- 3-carbamoyl-1-beta-D-ribofuranosylpyridinium hydroxide 5'-(dihydrogen phosphate) inner salt
- CS-4996
- ((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate
- CHEBI:16171
- CHEMBL610238
- b-NM
- AfAE'Adaggeratrade markAfA centA centasA notA em leaderA inverted exclamation mark-Nicotinamide mononucleotide
- 3-(AMINOCARBONYL)-1-(5-O-PHOSPHONO-.BETA.-D-RIBOFURANOSYL)PYRIDINIUM INNER SALT
- MFCD00038748
- -Nicotinamide mononucleotide
- .BETA.-D-NMN
- BETANMN
- CCG-267847
- J-002287
- EX-A3534
- DAYLJWODMCOQEW-TURQNECASA-N
- beta -Nicotinamide mononucleotide
- 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)pyridinium, inner salt
- SCHEMBL105618
- 3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium
- 3-(Aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)pyridinium inner salt
- UNII-2KG6QX4W0V
- HY-F0004
- Nicotinamidmononucleotid
- 3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1??-pyridin-1-ylium
- BDBM50366763
- ss-NMN
- AfAE'A centa' notA inverted exclamation markAfasA'A
- AS-59655
- EINECS 214-136-5
- bmse000260
- ?-Nicotinamidemononucleotide
- ss-Nicotinamide mononucleotide
-
- MDL： MFCD00038748
- Inchi： 1S/C11H15N2O8P/c12-10(16)6-2-1-3-13(4-6)11-9(15)8(14)7(21-11)5-20-22(17,18)19/h1-4,7-9,11,14-15H,5H2,(H3-,12,16,17,18,19)/t7-,8-,9-,11-/m1/s1
- InChI Key： DAYLJWODMCOQEW-TURQNECASA-N
- SMILES： P(=O)([O-])(O[H])OC([H])([H])[C@]1([H])[C@]([H])([C@]([H])([C@]([H])([N+]2=C([H])C([H])=C([H])C(C(N([H])[H])=O)=C2[H])O1)O[H])O[H]
- BRN： 3570187
Computed Properties
- Exact Mass: 334.05665
- Monoisotopic Mass: 334.05660244 g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 4
- Hydrogen Bond Acceptor Count: 8
- Heavy Atom Count: 22
- Rotatable Bond Count: 5
- Complexity: 455
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 4
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Molecular Weight: 334.22
- XLogP3: -3.5
- Topological Polar Surface Area: 166
Experimental Properties
- Color/Form: No data available
- Melting Point: No data available
- Boiling Point: No data available
- Flash Point: No data available
- Solubility: DMSO (Slightly, Heated), Methanol (Slightly), Water (Slightly)
- PSA: 166.25
- Merck: 6663
- λmax: 266(H2O)(lit.)
- Vapor Pressure: No data available
β-Nicotinamide Mononucleotide Security Information
- Signal Word：Warning
- Hazard Statement： H315-H319-H335
- Warning Statement： P261-P305+P351+P338
- Hazardous Material transportation number：NONH for all modes of transport
- WGK Germany：3
- Safety Instruction： H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
- FLUKA BRAND F CODES：8-10-21
- Storage Condition：4°C, protect from light
β-Nicotinamide Mononucleotide Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | N131850-25mg |
β-Nicotinamide Mononucleotide |
1094-61-7 | ≥95% | 25mg |
￥29.90 | 2023-09-01 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | N131850-25g |
β-Nicotinamide Mononucleotide |
1094-61-7 | ≥95% | 25g |
￥723.90 | 2023-09-01 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | N131850-500mg |
β-Nicotinamide Mononucleotide |
1094-61-7 | ≥95% | 500mg |
￥52.90 | 2023-09-01 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | N131850-100mg |
β-Nicotinamide Mononucleotide |
1094-61-7 | ≥95% | 100mg |
￥35.90 | 2023-09-01 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | N131850-5g |
β-Nicotinamide Mononucleotide |
1094-61-7 | ≥95% | 5g |
￥305.90 | 2023-09-01 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | N131850-1g |
β-Nicotinamide Mononucleotide |
1094-61-7 | ≥95% | 1g |
￥77.90 | 2023-09-01 | |
| DC Chemicals | DC32374-100 mg |
Nicotinamide Mononucleotide |
1094-61-7 | >99% | 100mg |
$150.0 | 2022-02-28 | |
| DC Chemicals | DC32374-250 mg |
Nicotinamide Mononucleotide |
1094-61-7 | >99% | 250mg |
$300.0 | 2022-02-28 | |
| DC Chemicals | DC32374-1g |
Nicotinamide Mononucleotide |
1094-61-7 | 1g |
$500.0 | 2023-09-15 | ||
| S e l l e c k ZHONG GUO | S5259-25mg |
β-Nicotinamide Mononucleotide |
1094-61-7 | 99.93% | 25mg |
￥794.91 | 2023-09-15 |
β-Nicotinamide Mononucleotide Suppliers
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
β-Nicotinamide Mononucleotide Related Literature
-
Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
-
Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
-
Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
-
5. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
Additional information on β-Nicotinamide Mononucleotide
Exploring the Potential of β-Nicotinamide Mononucleotide (CAS 1094-61-7) in Health and Longevity
In recent years, β-Nicotinamide Mononucleotide (often abbreviated as NMN and identified by CAS 1094-61-7) has emerged as a groundbreaking compound in the fields of anti-aging and metabolic health. As a precursor to nicotinamide adenine dinucleotide (NAD+), NMN plays a pivotal role in cellular energy production and DNA repair. This has sparked immense interest among researchers, health enthusiasts, and longevity seekers worldwide. The compound's ability to boost NAD+ levels—which decline with age—has positioned it as a potential key to unlocking healthier aging and improved vitality.
The scientific community has been particularly intrigued by how β-Nicotinamide Mononucleotide functions at the molecular level. Once ingested, NMN is rapidly converted into NAD+, a coenzyme essential for numerous biological processes. These include energy metabolism, mitochondrial function, and the activation of sirtuins—proteins linked to longevity. Studies suggest that supplementing with NMN may help counteract age-related declines in NAD+ levels, thereby supporting cognitive function, cardiovascular health, and even physical endurance. This has led to a surge in demand for NMN supplements, especially among those exploring cutting-edge approaches to wellness.
One of the most compelling aspects of β-Nicotinamide Mononucleotide is its potential application in addressing age-related conditions. Research indicates that NMN could play a role in mitigating oxidative stress, reducing inflammation, and enhancing insulin sensitivity. These properties make it a subject of interest for conditions like metabolic syndrome, neurodegenerative diseases, and even certain aspects of skin aging. As the global population ages, the search for safe and effective interventions to promote healthy aging has never been more urgent—and NMN appears to be at the forefront of this movement.
The market for β-Nicotinamide Mononucleotide has expanded rapidly, driven by both scientific advancements and growing consumer awareness. Online searches for terms like "NMN benefits," "best NMN supplement," and "NMN anti-aging" have skyrocketed, reflecting widespread curiosity about this compound. Manufacturers have responded with a variety of NMN products, ranging from powders to capsules, often marketed as part of premium longevity stacks. However, quality and bioavailability remain critical considerations, as not all NMN supplements are created equal.
Beyond supplementation, researchers are exploring innovative delivery methods for β-Nicotinamide Mononucleotide, including sublingual formulations and combination therapies with other NAD+ boosters like resveratrol. The compound's stability and absorption profile continue to be areas of active investigation, with new studies regularly contributing to our understanding of its optimal use. As clinical trials progress—particularly those examining NMN in human subjects—the scientific community anticipates more definitive answers about dosage, long-term effects, and specific health applications.
For those considering β-Nicotinamide Mononucleotide as part of their health regimen, it's important to consult with healthcare professionals and source high-quality products from reputable suppliers. While current evidence is promising, the field of NAD+ research is still evolving, and individual responses to NMN supplementation may vary. As interest in this remarkable compound grows, so does the need for accurate information and responsible use—making education about CAS 1094-61-7 and its potential benefits more valuable than ever.
1094-61-7 (β-Nicotinamide Mononucleotide) Related Products
- 321-02-8(Nicotinic acid mononucleotide)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
- 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
- 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
